Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APRE NASDAQ:CYTK NASDAQ:FREQ NASDAQ:GOSS NASDAQ:IMAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$1.46-3.6%$1.67$1.41▼$5.01$8.80M1.334,087 shs35,855 shsCYTKCytokinetics$49.76+0.6%$40.08$29.31▼$59.39$5.92B0.622.64 million shs2.01 million shsFREQFrequency Therapeutics$0.30$0.58$0.18▼$16.00$10.94M0.84822,537 shs309,164 shsGOSSGossamer Bio$3.20+0.6%$2.16$0.66▼$3.60$723.07M1.954.33 million shs3.46 million shsIMABI-Mab$3.72+2.8%$3.47$0.60▼$5.90$295.61M1.361.74 million shs1.19 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics-3.64%-6.13%-13.91%-17.69%-52.84%CYTKCytokinetics+0.65%-3.38%+28.68%+52.03%-12.32%FREQFrequency Therapeutics0.00%0.00%0.00%0.00%0.00%GOSSGossamer Bio+0.63%+15.52%+63.27%+148.06%+251.65%IMABI-Mab+2.76%-19.13%-23.61%+59.66%+250.94%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$1.46-3.6%$1.67$1.41▼$5.01$8.80M1.334,087 shs35,855 shsCYTKCytokinetics$49.76+0.6%$40.08$29.31▼$59.39$5.92B0.622.64 million shs2.01 million shsFREQFrequency Therapeutics$0.30$0.58$0.18▼$16.00$10.94M0.84822,537 shs309,164 shsGOSSGossamer Bio$3.20+0.6%$2.16$0.66▼$3.60$723.07M1.954.33 million shs3.46 million shsIMABI-Mab$3.72+2.8%$3.47$0.60▼$5.90$295.61M1.361.74 million shs1.19 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics-3.64%-6.13%-13.91%-17.69%-52.84%CYTKCytokinetics+0.65%-3.38%+28.68%+52.03%-12.32%FREQFrequency Therapeutics0.00%0.00%0.00%0.00%0.00%GOSSGossamer Bio+0.63%+15.52%+63.27%+148.06%+251.65%IMABI-Mab+2.76%-19.13%-23.61%+59.66%+250.94%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPREAprea Therapeutics 3.00Buy$15.50965.29% UpsideCYTKCytokinetics 2.87Moderate Buy$75.3851.50% UpsideFREQFrequency Therapeutics 0.00N/AN/AN/AGOSSGossamer Bio 3.00Buy$8.50165.63% UpsideIMABI-Mab 3.00Buy$7.0088.17% UpsideCurrent Analyst Ratings BreakdownLatest CYTK, FREQ, IMAB, GOSS, and APRE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/11/2025GOSSGossamer BioCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight9/10/2025IMABI-MabNew Street ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$7.009/9/2025IMABI-MabBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$7.009/8/2025IMABI-MabNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.009/3/2025CYTKCytokineticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$53.00 ➝ $71.009/3/2025CYTKCytokineticsEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$60.00 ➝ $80.009/2/2025CYTKCytokineticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy9/2/2025CYTKCytokineticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$77.00 ➝ $84.009/2/2025CYTKCytokineticsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$87.00 ➝ $96.009/2/2025CYTKCytokineticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$78.009/2/2025CYTKCytokineticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$72.00(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPREAprea Therapeutics$1.50M5.66N/AN/A$3.55 per share0.41CYTKCytokinetics$18.47M322.38N/AN/A($1.15) per share-43.27FREQFrequency Therapeutics$14.07M0.78N/AN/A$1.96 per share0.15GOSSGossamer Bio$114.70M6.34N/AN/A$0.13 per share24.62IMABI-Mab$3.89M78.09N/AN/A$2.47 per share1.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPREAprea Therapeutics-$12.96M-$2.32N/AN/AN/A-1,645.01%-78.90%-62.67%11/6/2025 (Estimated)CYTKCytokinetics-$589.53M-$5.10N/AN/AN/A-707.17%N/A-45.52%11/5/2025 (Estimated)FREQFrequency Therapeutics-$81.58M-$1.89N/AN/AN/AN/A-107.67%-61.40%N/AGOSSGossamer Bio-$56.53M-$0.62N/AN/AN/A-344.81%-1,774.72%-46.73%11/6/2025 (Estimated)IMABI-Mab-$22.23MN/A0.00N/AN/AN/A-19.65%-18.58%11/13/2025 (Estimated)Latest CYTK, FREQ, IMAB, GOSS, and APRE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/20/2025Q2 2025IMABI-Mab-$0.10-$0.07+$0.03-$0.07N/AN/A8/12/2025Q2 2025APREAprea Therapeutics-$0.77-$0.53+$0.24-$0.53N/A$0.12 million8/7/2025Q2 2025CYTKCytokinetics-$1.34-$1.12+$0.22-$1.12$1.95 million$66.77 million8/5/2025Q2 2025GOSSGossamer Bio-$0.18-$0.17+$0.01-$0.17$4.12 million$11.49 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPREAprea TherapeuticsN/AN/AN/AN/AN/ACYTKCytokineticsN/AN/AN/AN/AN/AFREQFrequency TherapeuticsN/AN/AN/AN/AN/AGOSSGossamer BioN/AN/AN/AN/AN/AIMABI-MabN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPREAprea TherapeuticsN/A5.345.34CYTKCytokineticsN/A6.766.76FREQFrequency TherapeuticsN/A5.815.81GOSSGossamer Bio6.704.404.40IMABI-MabN/A22.8222.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPREAprea Therapeutics34.19%CYTKCytokineticsN/AFREQFrequency Therapeutics13.18%GOSSGossamer Bio81.23%IMABI-Mab38.38%Insider OwnershipCompanyInsider OwnershipAPREAprea Therapeutics13.63%CYTKCytokinetics3.40%FREQFrequency Therapeutics16.80%GOSSGossamer Bio6.70%IMABI-Mab22.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPREAprea Therapeutics75.83 million5.03 millionNo DataCYTKCytokinetics250119.66 million115.59 millionOptionableFREQFrequency Therapeutics4636.52 million30.39 millionNot OptionableGOSSGossamer Bio180227.38 million212.15 millionOptionableIMABI-Mab38081.66 million63.61 millionOptionableCYTK, FREQ, IMAB, GOSS, and APRE HeadlinesRecent News About These CompaniesI-Mab (NASDAQ:IMAB) Earns Buy Rating from Analysts at BTIG ResearchSeptember 11, 2025 | marketbeat.comBTIG Research Begins Coverage on I-Mab (NASDAQ:IMAB)September 11, 2025 | americanbankingnews.comI-Mab: Sudden Pivot To Gastric Cancer Med Still Underappreciated By MarketSeptember 10, 2025 | seekingalpha.comNeedham & Company LLC Reaffirms Buy Rating for I-Mab (NASDAQ:IMAB)September 10, 2025 | marketbeat.comI-Mab (NASDAQ:IMAB) Given "Buy" Rating at Needham & Company LLCSeptember 10, 2025 | americanbankingnews.comBTIG Initiates Coverage of I-Mab - Depositary Receipt () (IMAB) with Buy RecommendationSeptember 9, 2025 | msn.comI-Mab initiated with a Buy at BTIGSeptember 9, 2025 | msn.comI-Mab Announces Leadership Changes and Accelerated Investment in GivastomigSeptember 9, 2025 | msn.comI-Mab announces accelerated investment in givastomig programSeptember 9, 2025 | msn.comI-Mab Announces Acceleration of Givastomig Investment and Leadership AppointmentsSeptember 9, 2025 | markets.businessinsider.comI-Mab to accelerate investment in givastomigSeptember 9, 2025 | msn.comI-Mab Sponsored ADR (NASDAQ:IMAB) Sees Large Increase in Short InterestSeptember 5, 2025 | marketbeat.comI-Mab Insiders Land Bargain With Gains Of US$5.0mAugust 31, 2025 | finance.yahoo.comAre You Looking for a Top Momentum Pick? Why I-Mab Sponsored ADR (IMAB) is a Great ChoiceAugust 28, 2025 | zacks.comStonepine Capital Management LLC Makes New $398,000 Investment in I-Mab Sponsored ADR $IMABAugust 26, 2025 | marketbeat.comHC Wainwright Comments on I-Mab's Q3 Earnings (NASDAQ:IMAB)August 26, 2025 | marketbeat.comI-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development CommitteeAugust 25, 2025 | globenewswire.comI-Mab (NASDAQ:IMAB) Upgraded by Wall Street Zen to "Buy" RatingAugust 25, 2025 | marketbeat.comNeedham & Company LLC Forecasts Strong Price Appreciation for I-Mab (NASDAQ:IMAB) StockAugust 23, 2025 | marketbeat.comI-Mab's (IMAB) Buy Rating Reiterated at HC WainwrightAugust 23, 2025 | marketbeat.comI-Mab (NASDAQ:IMAB) Announces Earnings Results, Beats Estimates By $0.03 EPSAugust 22, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCYTK, FREQ, IMAB, GOSS, and APRE Company DescriptionsAprea Therapeutics NASDAQ:APRE$1.46 -0.06 (-3.64%) Closing price 09/16/2025 03:59 PM EasternExtended Trading$1.51 +0.05 (+3.78%) As of 08:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Cytokinetics NASDAQ:CYTK$49.76 +0.32 (+0.65%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$50.02 +0.26 (+0.51%) As of 08:37 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Frequency Therapeutics NASDAQ:FREQFrequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.Gossamer Bio NASDAQ:GOSS$3.20 +0.02 (+0.63%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$3.30 +0.09 (+2.97%) As of 08:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.I-Mab NASDAQ:IMAB$3.72 +0.10 (+2.76%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$3.59 -0.13 (-3.49%) As of 08:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Rezolute Stock: FDA Fast Track Fuels 2025 Breakout Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
